Our new website is coming soon, give it a try now and let us have your feedback. Take me to the Beta



Register
Login:
Share:
Email Facebook Twitter

TSX Lithium explorer International Lithium Corp prepares to drill at Raleigh Lake Watch Now

TSX Lithium explorer International Lithium Corp prepares to drill at Raleigh Lake
Exclusive: Hardman & Co Investor Forum - Severn Trent, Calculus Capital, Volta Finance, Residential


Motif Bio Share Chat (MTFB)



Share Price: 3.175Bid: 3.05Ask: 3.30Change: 0.00 (0.00%)No Movement on Motif Bio
Spread: 0.25Spread as %: 8.20%Open: 3.25High: 0.00Low: 0.00Yesterday’s Close: 3.175


Share Discussion for Motif Bio




View all MTFB Messages

Please login or register to post a message on Share Chat.

Posts per page:

Lawson
Posts: 240
Opinion:No Opinion
Price:7.96
RE: Why didn’t the interviewer ask GL
24 May '19
Good one! We have a rather different use of this word in Oz. No slur on the bird.
 
jackdaw99
Posts: 814
Opinion:No Opinion
Price:7.96
RE: Why didn’t the interviewer ask GL
24 May '19
Drongo! That's a slur on a perfectly respectable bird.
Lawson
Posts: 240
Opinion:No Opinion
Price:8.00
RE: Why didn’t the interviewer ask GL
24 May '19
Dr A, We are lucky to have some incredibly well informed people on this forum and their posts are extremely educational , (I am not one of them) and we also have our own resident Drongo. Any way good luck with your investments.
AIMing_high
Posts: 867
Opinion:No Opinion
Price:7.70
RE: Why didn’t the interviewer ask GL
24 May '19
Two bits of (unsolicited advice)
1: take everything writtten in here with a huge pinch of salt
B: Aim is the Wild West and very hard to make money. You can win big if you get lucky, but an awful lot of “sure fire” winners crumble to nothing.

Best of luck
Dr.Anomaly
Posts: 3
Opinion:No Opinion
Price:8.00
RE: Why didn’t the interviewer ask GL
24 May '19
Thanks uddinkas, most of my investments are, I was taking a few steps with a set budget to see if share trading is for me. I have made some good buys with Unilever and other large corporates but thought I may try a small amount on a more 'risky' trade. I just need to get in my head, these forums are fun and informative, but to trust in my own decisions.
Citytilidie
Posts: 1,895
Opinion:No Opinion
Price:7.70
RE: Why didn’t the interviewer ask GL
24 May '19
No I haven’t Thai as I like to read his posts for entertainment value !

The desperation in his posts is almost palpable !
Georgerog
Posts: 43
Opinion:No Opinion
Price:7.70
RE: Why didn’t the interviewer ask GL
24 May '19
SP250- you sound quite desperate. You probably sold out and lost money and are quite bitter is my guess. You previously mentioned that GL failed to talk about skin infections in the AGM as it’s primary use. Well in this latest interview he clearly thinks treatment in skin infections are the primary goal with other side ventures. Care to comment?
Thaiflyer1
Posts: 102
Opinion:No Opinion
Price:7.70
RE: Why didn’t the interviewer ask GL
24 May '19
Not you SP250 said it...........you must have him on filter do you?
Citytilidie
Posts: 1,895
Opinion:No Opinion
Price:7.70
RE: Why didn’t the interviewer ask GL
24 May '19
At what stage did I say virtually insolvent ?
uddinkas
Posts: 666
Opinion:No Opinion
Price:7.70
RE: Why didn’t the interviewer ask GL
24 May '19
Dr.Anomaly, you should stick to tracker funds because if your investment decisions are dictated by anonymous derampers on a public bulletin boards then share investing is not for you.
Dr.Anomaly
Posts: 3
Opinion:No Opinion
Price:7.70
RE: Why didn’t the interviewer ask GL
24 May '19
Boom and virtually insolvent? You are one of the reasons I hastily sold a large chunk a few days ago. Please could you stop this - markets work on speculation, many other shares one could buy are companies that do not have structural assets to cover liabilities, hence the very reason shares are sold. If you feel this isn't the investment for you, great - but stop this tirade, please?
Ian.B
Posts: 15,583
Opinion:No Opinion
Price:7.70
RE: Why didn’t the interviewer ask GL
24 May '19
Option 2 - Post monitoring is still full approval to commercialise, however if the drug was causing serious issues to patients the FDA obviously remove its licence. (Rightly so)

The extensive trials suggests there will not be any serious issues.

I said 1200 patients earlier, ivy pointed out to me it is 1500. No liver damage caused in any of them.
InvestingWizard
Posts: 87
Opinion:No Opinion
Price:7.70
RE: Why didn’t the interviewer ask GL
24 May '19
@Jimzi: All that matters to me is clear pathway to approval. Options 1 and 2 give us that thereby removing the big cloud hanging over MTFB's head. Upon approval, the idea that MTFB is 30Million market company will sound preposterous. Market capitalization should rise to 250Million within weeks/few months after approval. The bolstering of the pipeline assets and the collaborations agreements are all designed to ensure MTFB gets a premium valuation number upon approval of Iclaprim.
ScottPalmer250
Posts: 397
Opinion:No Opinion
Price:7.70
RE: Why didn’t the interviewer ask GL
24 May '19
Boom and virtually insolvent is an interesting concept. Remind me not to come to you for a health evaluation
Jimzi
Posts: 11,450
Opinion:No Opinion
Price:7.70
RE: Why didn’t the interviewer ask GL
24 May '19
Is post market surveillance half approval? Main concern is how do fundraising peeps perceive it - all done to risk premiums/ discounts
DrMaccers
Posts: 3,010
Opinion:No Opinion
Price:7.70
RE: Why didn’t the interviewer ask GL
24 May '19
Given that 1/2 is the FDA saying you can have approval it should be boom time
Citytilidie
Posts: 1,895
Opinion:No Opinion
Price:7.70
RE: Why didn’t the interviewer ask GL
24 May '19
Given that we get option 1 or 2 how do we think the SP will react ? Slow climb back to the 40’s prior to Feb 14th or boom time ?
The.Italian
Posts: 1,299
Premium Chat Member
Opinion:No Opinion
Price:7.40
RE: Why didn’t the interviewer ask GL
24 May '19
as a complete layman in such matters i am starting to feel that post market monitoring is the most likely outcome.just speculation of course.
DrMaccers
Posts: 3,010
Opinion:No Opinion
Price:7.40
RE: Why didn’t the interviewer ask GL
24 May '19
Yes logically you run the trial again and you get the same outcome and then what? The FDA have learnt nothing new. If they want new info the only real option is post market monitoring. That’s more logical thinking than cloak and dagger disappearing webcasts ffs lol
Ian.B
Posts: 15,583
Opinion:No Opinion
Price:7.21
RE: Why didn’t the interviewer ask GL
24 May '19
Not quite the conference call took a question -

‘Did the fda indicate any requirement for any further trials in the CRL”

Answer - “no they did not”

That fact hasn’t changed the CRl did not indicate any further trials. - however GL still has to consider all 3 options open to the FDA now and rightly explained them.

I see Ivy concurs that’s further phae 3 trial will only show same results, ie that 2-3% of patients have raised liver enzymes and later return to normal with no damage.

It seems sensible to revisit those patients and see if that’s changed in any way??
ScottPalmer250
Posts: 397
Opinion:No Opinion
Price:7.21
Why didn’t the interviewer ask GL
24 May '19
You said no clinical trials in a conference call on the 19th Feb? What has changed? They keep going back to the 14th Feb RNS like the conference call never happened




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk









Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.